Best sequence for optimal targeted mRCC therapy remains elusive

The use of targeted therapies for metastatic renal cell carcinoma could see patients surviving in excess of 2 years, suggest findings from the Institut Gustave Roussy in Paris, France.
Source: MedWire News - Oncology - Category: Cancer & Oncology Source Type: news